Arrowhead says Australia TGA approves REDEMPLO for familial chylomicronemia syndrome
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. ARWR | 0.00 |
- Australia TGA cleared Arrowhead REDEMPLO (plozasiran) for adults with familial chylomicronemia syndrome as adjunct to diet to reduce triglycerides.
- Decision expands global access following prior authorizations in US, Canada, China.
- Approval backed by Phase 3 PALISADE data showing median 80% triglyceride reduction with 25 mg versus 17% with placebo.
- REDEMPLO is self-administered by subcutaneous injection once every three months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260501510547) on May 01, 2026, and is solely responsible for the information contained therein.